For Q3 of the fiscal year ending December 2026, consolidated revenue was 14,820 million yen (YoY +15.3%), Core operating loss was -2,804 million yen. Full-year revenue forecast remains 32,000 million yen, Core operating profit 4,600 million yen. Treasury shares at period-end: 1,442,676 shares. No dividend forecast; results disclosed on an IFRS basis.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4587","jir_company_name":"PeptiDream Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4587-20261111-01.pdf","jir_short_summary":"For Q3 of the fiscal year ending December 2026, consolidated revenue was 14,820 million yen (YoY +15.3%), Core operating loss was -2,804 million yen. Full-year revenue forecast remains 32,000 million yen, Core operating profit 4,600 million yen. Treasury shares at period-end: 1,442,676 shares. No dividend forecast; results disclosed on an IFRS basis.","jir_summary":"### Key Points of Financial Results\nThis financial summary discloses PeptiDream Inc.'s consolidated IFRS results for Q3 of the fiscal year ending December 2026. Revenue was 14,820 million yen, an increase of 15.3% year-over-year, but Core operating profit was a loss of -2,804 million yen and operating profit was a loss of -2,867 million yen. The dividend forecast remains 0 yen at this time with no change. Shares outstanding at period-end were 130,010,400 shares, and treasury shares were 1,442,676 shares.\n\n### Outlook and Factors\nThe full-year forecast indicates revenue of 32,000 million yen, Core operating profit of 4,600 million yen, and net income of 3,000 million yen, but as noted in the financial summary, attention should be paid to differences between Core-adjusted figures and IFRS figures including one-off items. As recently announced, there is no dividend and no earnings presentation will be held.","jir_financial_highlights":"Revenue: 14,820 (YoY for same quarter +15.3%)\nCore Operating Profit: -2,804 (-)\nOperating Profit: -2,867 (-)\nNet Income Attributable to Owners of Parent (Quarter): -2,362 (-)\nTotal Assets: 71,151 (-)\nTreasury Shares: 1,442,676 shares (Prior period: 796,435 shares \u2192 increase)","jir_category":"","jir_hashtags":"#PeptiDreamInc., #FinancialResults, #Radiopharmaceuticals, #PDPS","jir_key_figures":"Revenue: 14,820 million yen (YoY for same quarter +15.3%)\nOperating Loss: -2,867 million yen\nNet Income Attributable to Owners of Parent (Quarter): -2,362 million yen","jir_meta_title":"PeptiDream Inc. Q3 FY2026 Financial Results | Revenue 14,820 million yen, Narrowing Net Loss","jir_meta_description":"PeptiDream Inc. Q3 FY2026 financial results. IFRS-based revenue: 14,820 million yen. Core operating loss: -2,804 million yen. Full-year forecast: 32,000 million yen. No dividend. Increase in treasury shares. Summary of key notes.","jir_og_title":"PeptiDream Inc. | Q3 FY2026 Financial Results Overview","jir_og_description":"PeptiDream Inc.'s Q3 results: revenue 14,820 million yen, Core operating loss 2,804 million yen. Full-year forecast 32,000 million yen, no dividend. See notes for outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-Q3\\\",\\\"2026-Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[12857,14820]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-Q3\\\",\\\"2026-Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit\\\",\\\"data\\\":[-3979,-2804]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Drug Discovery and Development Business\\\",\\\"Radiopharmaceuticals Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1130,12746]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Loss Margin\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Loss\\\",\\\"data\\\":[-4058,-2867]}]},\\\"options\\\":{}}\"}]","ir_related_company":8926,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149185","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n